Severe hypoglycaemia during treatment with glipizide

Area of Science:

• Endocrinology
• Pharmacovigilance
• Geriatrics

Background:

• Glipizide is a commonly prescribed oral hypoglycemic agent for type 2 diabetes.
• Severe hypoglycemia is a significant adverse event associated with sulfonylurea medications.
• Elderly patients and those with comorbidities may be at increased risk.

Purpose of the Study:

• To investigate the characteristics and outcomes of severe hypoglycemia associated with glipizide treatment.
• To identify risk factors for glipizide-induced severe hypoglycemia.

Main Methods:

• Retrospective analysis of reported cases to the Swedish Adverse Drug Reactions Advisory Committee (1980-1987).
• Case-control substudy comparing patients with glipizide-associated hypoglycemia to matched controls.
• Assessment of patient demographics, clinical presentation, treatment duration, concomitant medications, and renal function.

Main Results:

• Nineteen cases of severe hypoglycemia were reported in patients aged 75 +/- 9 years.
• Hypoglycemia presented with coma (11 cases), reduced consciousness (3 cases), or other symptoms (5 cases).
• Renal impairment was more frequent in hypoglycemic patients (OR 4.0), and concomitant medication use was higher (median 5 vs 2 drugs).
• Prolonged or recurrent hypoglycemia occurred in 5 patients, with 2 deaths in those with complicating disorders.

Conclusions:

• Glipizide treatment is associated with a risk of severe hypoglycemia, particularly in elderly patients.
• Renal impairment and polypharmacy are significant risk factors for glipizide-induced hypoglycemia.
• The clinical course of severe hypoglycemia can be prolonged or recurrent, with potential for fatal outcomes.